NEW YORK (GenomeWeb News) – Genomic Health said after the close of the market on Friday that the national Medicare contractor for the firm's Oncotype DX breast cancer test has expanded Medicare coverage for the test.

The contractor, Palmetto GBA, has expanded its coverage policy for all qualified Medicare patients to include those with ductal carcinoma in situ, or DCIS, Genomic Health said. The coverage policy took effect May 8.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: the Human Silencing Hub protein complex, and more.

Heads of various research funding agencies discuss how to encourage scientific breakthroughs, ScienceInsider reports.

The Kansas City Star examines issues surrounding newborn genome sequencing.

Researchers say their Research Resource Identifier citation format is catching on, Nature News reports.